Endpoint Ventures
VC Fund
Endpoint Ventures is a VC fund focused on Health Care and Medical. Early stage healthcare, therapeutics, diagnostics, and life sciences investing
- Total investments:
- 10
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Endpoint Ventures invests in
Health CareMedicalBiotechnologyGeneticsTherapeutics
Stages Endpoint Ventures invests in
SeedPre-SeedSeries AFunding Round
Countries Endpoint Ventures invests in
United StatesCanada
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Diego Rey
|
|||
Investment Focus
Industry
- Health Care 6 (60%)
- Medical 5 (50%)
- Biotechnology 5 (50%)
- Genetics 2 (20%)
- Therapeutics 2 (20%)
Stage
- Seed 6 (60%)
- Pre-Seed 1 (10%)
- Series A 1 (10%)
- Funding Round 1 (10%)
Country
- United States 8 (80%)
- Canada 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Diego Rey
Partner
|
Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Indee Labs
|
Indee Labs is developing hardware for gene delivery. Our hardware is uniquely positioned for the efficient development and scalable manufacture of gene-modified cell therapies such as chimeric antigen receptor T cells.The technology is being developed with the help of the Australian National Fabrication Facility. We are alumni of NSW Health,IndieBio, Y Combinator and MBC Biolabs (née QB3@953). We are opening up an office in Sydney and have lab space at Bonneville Labs in Berkeley. | Seed / Nov 02, 2020 | |
Shasqi
|
Shasqi is leading the development of therapeutics leveraging click chemistry to get active cancer treatments to tumors with its proprietary CAPAC™ (Click Activated Protodrugs Against Cancer) platform. The technology is based on localizing a click chemistry reagent in the tumor area, which then activates a second agent, a systemically infusedprotodrug. When the two ‘click’, a powerful localized therapy is activated at the tumor, while keeping its systemic exposure levels below toxic thresholds. We have already proven that our platform works in humans, which opens up an array of future possibilities for click-chemistry based therapies. | $10M / Series A / Oct 31, 2019 | |
Viosera Therapeutics
|
Viosera Therapeutics is a predict and block drug resistance in cancer and bacteria. The company discovers synergies between approved drugs and develop combinations of drugs that suppress resistance. Antibiotic resistance makes it necessary to develop better treatments for deadly infections.Viosera Therapeutics was founded in July 2016 and isheadquartered in Sunnyvale, California. | $150K / Seed / Mar 18, 2019 | |
FidoCure
|
FidoCure is transforming canine cancer care through AI-driven precision medicine. By harnessing data from naturally occurring canine cancers via next-generation sequencing and clinical information, FidoCure has developed the world's largest proprietary learning database for canine cancer. FidoCure is pioneering first-in-class care for caninecancer, which represents the largest unmet need for pet dogs. By connecting human and veterinary oncology, FidoCure enhances comparative oncology, improves outcomes across species, and creates new opportunities for drug development that benefit both pets and humans. | $5M / Seed / Jan 23, 2019 | |
Synkrino Biotherapeutics
|
Synkrino Biotherapeutics is a biotech platform that discovers and develops novel drug targets directly from the immune system of patients. The platform is providing monitoring for pediatric rheumatologists for life-threatening conditions. It is currently building a rapid, portable field test for the RNA virus 2019-nCoV/COVID-19, adapting itsexisting analytic protocols for community public health screening.Synkrino Biotherapeutics' therapeutics use AI + Immunology Discovery Engine (AIDE Engine) which applies neural networks and machine learning to measure the immune tissue from patients to repeatably discover novel and biologically-valid drug targets, enabling healthcare providers to cure their patients and improve their lives. | Seed / Aug 23, 2018 | |
Meru Health
|
Meru Health offers a digital program that helps improve the lives of people living with depression and saves on healthcare costs. It develops and delivers cost-effective, clinically proven, and engaging digital solutions to empower people living with depression.Founded by Kristian Ranta, Albert Nazander, and Riku Lindholm in 2015, Meru Health isheadquartered in San Mateo, California. | Jun 25, 2018 | |
Reverie Labs
|
Reverie Labs (YC W18) is building a pharma company from scratch, using computation. Reverie Labs accelerates preclinical drug development by applying machine learning to lead generation & optimization. | Seed / Mar 16, 2018 | |
HelpWear
|
HelpWear is striving to achieve better at-home healthcare by developing affordable and accessible products for patients all around the world. HelpWear’s focus is clinical need driven innovation, designing solutions to not only what a patient would need, but from a clinical perspective, to what the healthcare system requires as well. | Pre-Seed / Nov 02, 2017 | |
BillionToOne
|
BillionToOne is a precision diagnostics company that quantifies biology to create molecular diagnostics accurate, efficient, and accessible for all. The company's patent-pending molecular counter platform is a technology platform that can accurately count the DNA molecules to the single-count level. BillionToOne's mission is to makepre-natal testing safe and affordable for every expecting mother. Its novel technology can detect even single-gene disorders such as thalassemia through a simple blood test. They are replacing amniocentesis, an invasive and risky procedure that has a high miscarriage risk, with a safe and affordable blood test, starting in developing countries.BillionToOne was founded in 2016 and is headquartered in Menlo Park, California. | $2.4M / Seed / Sep 15, 2017 | |
|
BillionToOne
|
BillionToOne is a precision diagnostics company that quantifies biology to create molecular diagnostics accurate, efficient, and accessible for all. The company's patent-pending molecular counter platform is a technology platform that can accurately count the DNA molecules to the single-count level. BillionToOne's mission is to makepre-natal testing safe and affordable for every expecting mother. Its novel technology can detect even single-gene disorders such as thalassemia through a simple blood test. They are replacing amniocentesis, an invasive and risky procedure that has a high miscarriage risk, with a safe and affordable blood test, starting in developing countries.BillionToOne was founded in 2016 and is headquartered in Menlo Park, California. | Seed / Aug 21, 2017 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
Health Care Investors in United States
21,541 investors
FAQ
What does Endpoint Ventures invest in?
Endpoint Ventures invests primarily in Health Care, Medical and Biotechnology startups, most often at Seed and Pre-Seed stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Endpoint Ventures?
Public channels for Endpoint Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Endpoint Ventures?
The team at Endpoint Ventures includes Diego Rey (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
